Cardiac and vascular hypertrophy in Fabry disease: Evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition

被引:93
作者
Barbey, F
Brakch, N
Linhart, A
Rosenblatt-Velin, N
Jeanrenaud, X
Qanadli, S
Steinmann, B
Burnier, M
Palecek, T
Bultas, J
Hayoz, D [1 ]
机构
[1] CHU Vaudois, Dept Vasc Med, CH-1011 Lausanne, Switzerland
[2] CHU Vaudois, Dept Nephrol, CH-1011 Lausanne, Switzerland
[3] Charles Univ Prague, Sch Med 1, Dept Internal Med 2, CR-11636 Prague 1, Czech Republic
[4] CHU Vaudois, Dept Radiol, CH-1011 Lausanne, Switzerland
[5] CHU Vaudois, Dept Cardiol, CH-1011 Lausanne, Switzerland
[6] Dept Metab & Mol Pediat, Zurich, Switzerland
关键词
Fabry disease; growth-promoting factor; intima-media thickness; left ventricular hypertrophy;
D O I
10.1161/01.ATV.0000209649.60409.38
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives - Fabry disease is an X-linked disorder resulting from alpha-galactosidase A deficiency. The cardiovascular findings include left ventricular hypertrophy (LVH) and increased intima-media thickness of the common carotid artery (CCA IMT). The current study examined the possible correlation between these parameters. To corroborate these clinical findings in vitro, plasma from Fabry patients was tested for possible proliferative effect on rat vascular smooth muscle cells ( vascular smooth muscle cell [VSMC]) and mouse neonatal cardiomyocytes. Methods and Results - Thirty male and 38 female patients were enrolled. LVH was found in 60% of men and 39% of women. Increased CCA IMT was equally present in males and females. There was a strong positive correlation between LV mass and CCA IMT (r(2) = 0.27; P < 0.0001). VSMC and neonatal cardiomyocyte proliferative response in vitro correlated with CCA IMT (r(2) = 0.39; P < 0.0004) and LV mass index (r(2) = 0.19; P = 0.028), respectively. Conclusions - LVH and CCA IMT occur concomitantly in Fabry suggesting common pathogenesis. The underlying cause may be a circulating growth-promoting factor whose presence has been confirmed in vitro.
引用
收藏
页码:839 / 844
页数:6
相关论文
共 32 条
  • [1] Barbey F, 2004, Curr Med Chem Cardiovasc Hematol Agents, V2, P277, DOI 10.2174/1568016043356192
  • [2] BARBEY F, 2002, ACTA PAEDIAT S, V439
  • [3] Arterial remodelling in Fabry disease
    Boutouyrie, P
    Laurent, S
    Laloux, B
    Lidove, O
    Grunfeld, JP
    Germain, DP
    [J]. ACTA PAEDIATRICA, 2002, 91 : 62 - 66
  • [4] Non-invasive evaluation of arterial involvement in patients affected with Fabry disease
    Boutouyrie, P
    Laurent, S
    Laloux, B
    Lidove, O
    Grunfeld, JP
    Germain, DP
    [J]. JOURNAL OF MEDICAL GENETICS, 2001, 38 (09) : 629 - 631
  • [5] Natural history of Fabry renal disease -: Influence of α-galactosidase A activity and genetic mutations on clinical course
    Branton, MH
    Schiffmann, R
    Sabnis, SG
    Murray, GJ
    Quirk, JM
    Altarescu, G
    Goldfarb, L
    Brady, RO
    Balow, JE
    Austin, HA
    Kopp, JB
    [J]. MEDICINE, 2002, 81 (02) : 122 - 138
  • [6] FABRY DISEASE - IMPAIRED AUTONOMIC FUNCTION
    CABLE, WJL
    KOLODNY, EH
    ADAMS, RD
    [J]. NEUROLOGY, 1982, 32 (05) : 498 - 502
  • [7] FUNCTIONAL DEFECT IN AMYLOID HEART-DISEASE - STIFF-HEART SYNDROME
    CHEW, C
    ZIADY, GM
    RAPHAEL, MJ
    OAKLEY, CM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1975, 36 (04) : 438 - 444
  • [8] Similarities and differences in structural and functional changes of left ventricle and carotid arteries in young borderline hypertensives and in athletes
    Cuspidi, C
    Lonati, L
    Sampieri, L
    Leonetti, G
    Zanchetti, A
    [J]. JOURNAL OF HYPERTENSION, 1996, 14 (06) : 759 - 764
  • [9] ENZYME THERAPY IN FABRY DISEASE - DIFFERENTIAL INVIVO PLASMA-CLEARANCE AND METABOLIC EFFECTIVENESS OF PLASMA AND SPLENIC ALPHA-GALACTOSIDASE-A ISOZYMES .12.
    DESNICK, RJ
    DEAN, KJ
    GRABOWSKI, G
    BISHOP, DF
    SWEELEY, CC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (10) : 5326 - 5330
  • [10] Desnick RobertJ., 2001, The Metabolic and Molecular Bases of Inherited Disease, V8th, P3733, DOI DOI 10.1036/ommbid.181